Phosphodiesterase-5 inhibitor in eisenmenger syndrome: A preliminary observational study

Circulation

Volumn 114, Issue 17, 2006, Pages 1807-1810

  Mukhopadhyay, Saibal ^a   Sharma, Manish ^a   Ramakrishnan, S ^a   Yusuf, Jamal ^a   Gupta, Mohit Dayal ^a   Bhamri, Naveen ^a   Trehan, Vijay ^a   Tyagi, Sanjay ^a  

^a G B PANT HOSPITAL   (India)

Author keywords

Eisenmenger Complex; Hypertension, pulmonary; Phosphodiesterase inhibitors; Pulmonary heart disease; Tadalafil

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; TADALAFIL;

ADULT; ARTERIAL PRESSURE; ARTICLE; BODY WEIGHT; CARDIAC PATIENT; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EISENMENGER COMPLEX; FEMALE; HEMODYNAMICS; HUMAN; HYPOTENSION; LUNG VASCULAR RESISTANCE; MALE; OXYGEN SATURATION; PATIENT SELECTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT; VASCULAR RESISTANCE; WORLD HEALTH ORGANIZATION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADULT; CARBOLINES; EISENMENGER COMPLEX; EXERCISE TOLERANCE; FEMALE; HUMANS; MALE; OXYGEN; PHOSPHODIESTERASE INHIBITORS; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 33750553816     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.603001     Document Type: Article

References (17)

1. Vongpatanasin W, Brickner ME, Hillis LD, Lange RA. The Eisenmenger syndrome in adults. Ann Intern Med. 1998;128:745-755.
2. McLaughlin VV. Classification and epidemiology of pulmonary hypertension. Cardiol Clin. 2004;22:327-341.
3. Michelakis ED. The role ofNOaxis and its therapeutic implications in pulmonary arterial hypertension. Heart Fail Rev. 2003;8:5-21.
4. Michelakis E, Tymchak W, Lein D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002;105:2398-2403.
5. Michelakis E, Tymchak W, Noga M, Webster L, Wu XC, Lein D, Wang SH. Long term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation. 2003;108:2066-2069.
6. Kothari SS, Duggal B. Chronic oral sildenafil therapy in severe pulmonary artery hypertension. Indian Heart J. 2002;54:404-409.
7. Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Hardza P, Karadas B, Schermuly RT, Weissman N, Seeger W, Grimminger F. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2004;44:1488-1496.
8. Raffy O, Azarian R, Brenot F, Parent F, Sitbon O, Petitpretz P, Hervé P, Duroux P, Dinh-Xuan AT, Simonneau G. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation. 1996;93:484-488.
9. Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol. 1994;266:1536-1543.
10. Rosenthal E. Sildenafil use in patients with the Eisenmenger syndrome. Circulation. 2004;109:e197.
11. Brock GB, McMohan CG, Chen KK, Costigan T, Shen W, Watkins V, Anglin G, Whitaker S. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002;168:1332-1336.
12. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-2157.
13. Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract. 2002;56:453-459.
14. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:13S-24S.
15. Tantini B, Manes A, Fiumana E, Pignatti C, Guarnieri C, Zannoli R, Branzi MD A, Galiè N. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol. 2005;100:131-138.
16. Gatzoulis MA, Rogers P, Li W, Harries C, Cramer D, Ward S, Mikhail GW, Gibbs JS. Safety and tolerability of bosentan in adults with Eisenmenger physiology. Int J Cardiol. 2005;98:147-151.
17. Galie N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M, for the Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48-54.